1. Medtech Insight
  2. >>Digital Technologies

Start-Up Spotlight: BioIntelliSense Launches New FDA-Cleared BioSticker For Remote Monitoring Of Patients' Vital Signs

 
• By Marion Webb

BioIntelliSense is getting ready to trial its newly FDA-cleared BioSticker in patients at Colorado-based hospital network UCHealth for remote monitoring of vital signs.

Start-up Spotlight

This quarter, Denver, CO-based start-up BioIntelliSense and its strategic partner, UCHealth, will begin clinical testing of the BioSticker, a wearable sensor designed to remotely monitor patients' vital signs that was recently cleared by the US Food and Drug Administration.

The data from the wearable device will help clinicians identify physiological changes early enough to intervene before patients get sicker...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

Tandem Gears Up For Mobi Tubeless Launch In 2026 After ‘Year Of Transformation’

 
• By Marion Webb

Tandem Diabetes Care is positioning for growth in 2026 with the launch of its Mobi Tubeless pump following FDA clearance of its Android-compatible Mobi app while navigating multiple recalls during what CEO John Sheridan called a transformative year.

Can Chatbots Treat Depression? FDA Advisers Urge Caution on Generative AI Tools

 
• By Elizabeth Orr

FDA advisers gave a cautious nod to the idea of using generative AI in mental healthcare during a Nov. 6 panel meeting, saying evidence-backed tools could help expand access – but warning that safety, oversight, and the irreplaceable human connection remain major unanswered questions.

BCI Maker INBRAIN Inks Deal With Microsoft To Explore Agentic AI Use For Monitoring Patients

 
• By Marion Webb

INBRAIN teamed up with Microsoft to apply agentic AI to analyze real-time brain data and eventually recommend programming like a “mini-neurologist,” said CEO Carolina Aguilar. It also seeks to enable scalable deployment of INBRAIN’s graphene-based technology and potential joined research.

Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’

 
• By Marion Webb

Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.

More from Medtech Insight

US FDA Appropriations Cut In Proposed Shutdown-Ending Agreement

 
• By Derrick Gingery

But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.

Stryker Eyes Double-Digit Inari Growth Through Early 2026, With Global Expansion To Follow

 
• By Shubham Singh

Record Mako installations in the third quarter fueled growth across Stryker’s orthopedics portfolio, supporting higher revenue in the “Ortho Other” category. Executives said new product launches and software upgrades are broadening clinical applications.

Can Chatbots Treat Depression? FDA Advisers Urge Caution on Generative AI Tools

 
• By Elizabeth Orr

FDA advisers gave a cautious nod to the idea of using generative AI in mental healthcare during a Nov. 6 panel meeting, saying evidence-backed tools could help expand access – but warning that safety, oversight, and the irreplaceable human connection remain major unanswered questions.